A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND)
← catalyst calendarSponsored by Biogen (industry) · BIIB — their whole pipeline →.
Phase
Phase 4
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
46actual
Sites
15
Countries
Germany, Israel, Italy +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-01-04 | actual | When the study began enrolling |
| Primary completion | 2025-10-09 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-09 | actual | The whole study's end, after follow-up |
| First posted | 2020-07-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Muscular Atrophy, Spinal
Intervention
- Drug: Nusinersen — also filed as ISIS 396443, BIIB058, Spinraza
Primary outcome
what the primary-completion date above is the date OFTotal Hammersmith Infant Neurological Examination (HINE) Section 2 Motor Milestones Score
measured Up to Day 778
Publications
- PMID 40956616 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · BIIB's whole pipeline · Catalyst calendar · Every registered study · What changed